Novavax reports Q4 EPS ($1.44), consensus (45c)

Reports Q4 revenue $291M, consensus $321.97M. Cash, cash equivalents and restricted cash were $584M as of December 31, 2023, compared to $666M as of September 30, 2023. “2023 was a transition year for Novavax and we have made tremendous progress towards strengthening the financial profile of the Company, delivering the only protein-based non-mRNA COVID-19 vaccine option to the U.S. and globally, and focusing our investment on the future expansion of our product portfolio,” said John C. Jacobs, President and CEO Novavax. “Moving into the next chapter of our business journey as a more lean and agile organization, we are laser focused on improving our commercial performance in 2024 and 2025 and diversifying our revenue opportunity with our potential combination vaccine launch which we expect in the fall of 2026.”